Apricus Biosciences launches topical ED treatment in Germany
- Vitaros (alprostadil) is a topical treatment for erectile dysfunction. It has already been launched in the UK and in Sweden, making Germany its third market.
- Apricus has an exclusive licensing agreement with Sandoz to market Vitaros throughout the EU, including in Austria, Belgium, Denmark, Finland, Iceland, Luxemburg, the Netherlands, Norway, Sweden, Switzerland, and Germany.
- Apricus may receive as much as $63 million from Sandoz based on the agreement.
The erectile dysfunction (ED) market in the EU is estimated to be roughly $1.3 billion. Analysts are estimating peak Vitaros sales of $300 million.
Apricus has structured marketing relationships with various partners and anticipates up to $200 million altogether in royalty and milestone payments.
- Pharmaceutical Business Review Apricus Biosciences announces launch of topical treatment for erectile dysfunction vitaros in Germany by Hexal